EDUARDO
DÍAZ-RUBIO GARCÍA
Investigador hasta 2020
Hospital Regional Universitario de Málaga
Málaga, EspañaPublicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (19)
2023
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
2019
-
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Scientific Reports, Vol. 9, Núm. 1
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
2018
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
2014
-
TTD consensus document on the diagnosis and management of exocrine pancreatic cancer
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878
2013
-
Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»
Revista Espanola de Patologia
2012
-
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study
Oncologist, Vol. 17, Núm. 7, pp. 947-955
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study
Oncologist, Vol. 17, Núm. 3, pp. 339-345
-
Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon
Revista Espanola de Patologia
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2009
-
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Annals of Oncology, Vol. 20, Núm. 2, pp. 251-257
2001
-
Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial
Clinical colorectal cancer, Vol. 1, Núm. 1, pp. 43-46
1998
-
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
Annals of Oncology, Vol. 9, Núm. 1, pp. 105-108